ALPEGA
16.7.2024 10:01:29 CEST | Business Wire | Press release
Alpega is excited to announce the return of Connecta, the premier networking event in the European road transport sector, celebrating its 14th edition. Scheduled for October 10th and 11th, 2024, at the prestigious Marriott Auditorium Conference Center in Madrid, this year's event promises to be the most comprehensive and impactful yet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716487251/en/
(Photo: Business Wire)
Unparalleled Networking Opportunities
With over 500 professionals from across Europe expected to attend, Connecta 2024 will offer unmatched networking opportunities. Participants can generate significant business prospects within a single day, thanks to a meticulously planned agenda of networking activities. This event brings together the major players in the market, offering attendees a unique platform to engage in meaningful conversations and forge valuable connections.
A Full Logistics Network Representation
For the first time, Connecta 2024 will feature all logistics network participants, including carriers, freight forwarders, and shippers. This comprehensive representation ensures a holistic view of the industry, facilitating deeper insights and collaboration across different segments of the transport sector.
Showcasing the Latest Innovations
Connecta 2024 will also be a platform to showcase the latest innovations in the logistics sector. Attendees will have the opportunity to explore cutting-edge solutions and technologies that are transforming the industry, providing valuable insights into future trends and advancements.
Expanded Agenda with Key Panels and Workshops
The 2024 edition of Connecta boasts an expanded agenda, beginning on Thursday afternoon with a series of key panels and workshops. We are excited to confirm an inaugural session with Boston Consulting Group (BCG), led by Jesus Montero, Lead Knowledge Analyst in Logistics, presenting insightful analysis on industry trends alongside major sector players. Additionally, attendees can look forward to a networking workshop led by the renowned Jose Maria Salles, providing practical tools and strategies for effective networking.
Why Attend Connecta 2024?
“Connecta is more than just a networking event; it's a pivotal moment for the European logistics community to come together, share insights, and drive innovation. This year's edition will be our most impactful yet, offering unparalleled opportunities to connect, learn, and grow,” said Todd DeLaughter, CEO of Alpega.
- Engage with Industry Leaders: Meet and converse with top influencers and decision-makers in the European road transport industry.
- Generate Business Opportunities: Utilize tailored networking activities to create valuable business prospects in a single day.
- Gain Industry Insights: Attend sessions and panels led by industry experts, including a detailed analysis of current trends by BCG.
- Comprehensive Network Representation: Benefit from the presence of carriers, logistics operators, and shippers, offering a complete view of the transport chain.
- Discover Innovations: Explore the latest technologies and solutions shaping the future of logistics.
Don’t miss this unparalleled opportunity to connect, learn, and grow within the European road transport sector. Join us at Connecta 2024 and be part of the conversation shaping the future of the industry.
Registration and Additional Information
For more details and to register for Connecta 2024, please visit our official website Alpega Connecta. Special early bird prices are available until July 31st.
About Alpega
Alpega is a global leader in logistics SaaS software, dedicated to delivering comprehensive end-to-end solutions for all transport requirements. Our mission is to empower shippers, forwarders, and carriers through efficient digitalization, addressing today’s logistics challenges and driving smarter logistics for a greener tomorrow.
Leveraging extensive carrier-based assets, Alpega provides tangible benefits in Transport Execution, Freight Planning, Freight Sourcing and Payment, Dock Scheduling, and Data Insights. As the only SaaS provider offering Transport Management Systems (TMS) for shippers, and with an 80,000-strong open carrier network that covers about 10% of all commercial trucks in Europe, we lead in innovation and efficiency.
Our connectivity extends through three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and Southeastern European regions, facilitating seamless matching of freight loads with transportation capacity.
With over three decades of transportation expertise, we help businesses streamline their supply chain planning and execution, reducing costs and increasing visibility. Our community of 80,000 carriers and 200,000 members is seamlessly connected daily, efficiently managing vital transport operations. This network harnesses the power of collective intelligence, driving data-driven insights and optimizations across the logistics ecosystem, and creating a network effect that adds significant value for our customers. Operating in 80 countries, Alpega boasts a diverse team of over 450+ professionals representing 31 nationalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716487251/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom